PCT WORLD ORGANISATION FOR INTELLECTUAL PROPERTY
International Office
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International patent classification[6] : A61K 39/385

A1

(11) International publication number: WO 96/37222

(43) International publication date: 28 November 1996 (28.11.96)

(21) International application number: PCT/FR96/00791

(22) International filing date: 24 May 1996 (24.05.96)

(30) Data relating to the priority:
95/06,417 24 May 1995 (24.05.95) FR

(71) Applicant (for all designated States except US): PASTEUR MERIEUX SERUMS ET VACCINS S.A. [FR/FR]; 58, avenue Leclerc, F-69007 Lyon (FR).

(72) Inventors; and
(75) Inventors/Applicants (US only): François ARMINJON [FR/FR]; 17, boulevard de la Croix-Rousse, F-69004 Lyon (FR). Jean-René CARTIER [FR/FR]; 55, rue Jolio-Curie, F-69005 Lyon (FR).

(74) Representative: Danièle KERNEIS; Pasteur Merieux Sérums et Vaccins, Industrial Property Directorate, 58, avenue Leclerc, F-69007 Lyon (FR).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO Patent (KE, LS, MW, SD, SZ, UG), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With the International Search Report.
Before expiry of the period provided for amending the claims, will be republished if such amendments are received.

As printed

(54) Title: VACCINE COMPOSITION CONTAINING POLYRIBOSYLRIBITOL PHOSPHATE AND METHOD FOR MAKING SAME

(54) Titre: COMPOSITION VACCINALE COMPRENANT DU POLYRIBOSYLRIBITOL PHOSPHATE ET SON PROCEDE DE FABRICATION

(57) Abstract

A vaccine composition containing one or more antigens comprising the high molecular weight capsular polysaccharide of type b Haemophilus influenza, or polyribosylribitol phosphate, coupled to the tetanus toxoid and an aluminium-based adjuvant, wherein the aluminium-based adjuvant has, in its natural state, or following anion addition, a zero point of charge of less than about 7.2. A method for making said vaccine composition is also described.

(57) Abrégé

L'invention concerne une composition vaccinale comprenant au moins un antigène constitué par le polysaccharide capsulaire de Haemophilus influenzae type b ou Polyribosylribitol Phosphate à haut poids moléculaire couplé à l'anatoxine tétanique ainsi qu'un adjuvant à base d'aluminium, dans lequel l'adjuvant à base d'aluminium présente par nature ou après addition d'anions un point de charge zéro inférieur à environ 7.2. L'invention à également pour objet un procédé de fabrication d'une telle composition vaccinale.